Marco Cavaleri, EMA’s head of vaccine strategy, on vaccines developed by Novavax, Curevac, Sputnik V, Sinovac and Sanofi “We believe we can move towards a possible outcome towards the end of this year or early next year for at least the majority of these vaccines.” used the phrases.
Cavaleri stressed the need for some data before final approval can be given.
Vaccines currently approved in the EU have been developed by Pfizer-BioNTech, Moderna, AstraZeneca, and Johnson and Johnson.
The EMA is also reviewing an application for the 3rd dose of the Pfizer-BioNTech vaccine to be administered as a supplement.
EMA officials state that the evaluation will use data from a clinical study involving 300 adults who were given a third dose as a supplement 6 months after the second.
EMA states that the studies on the best time for the 3rd dose are still ongoing, and that the conclusion on the supplementary dose can be reached in a few weeks.
Source: A HABER by www.ahaber.com.tr.
*The article has been translated based on the content of A HABER by www.ahaber.com.tr. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!